drugset
drugset / Trial / NCT05963100

Clinical Study of TCR-like CAR-T Cell Targeted MSLN in the Treatment of Ovarian Cancer

NCT05963100 ↗

Phase 1/2 Active not recruiting 10 enrolled Zhongda Hospital
Non-randomizedSequentialOpen-labelTreatment

Summary

The goal of this clinical trial is to test TCR-like CAR-T in the Treatment of MSLN positive Ovarian Cancer. The main question it aims to answer are: the safety and efficacy of TCR-like CAR-T in the Treatment of MSLN positive Ovarian Cancer.

Timeline

Start
2023-08-07
Primary completion
2026-05-16
Completion
2026-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject TCR-like CAR-T Cell therapy 1e+06 cells/kg Intravenous
Subject TCR-like CAR-T Cell therapy 3e+06 cells/kg Intravenous
Subject TCR-like CAR-T Cell therapy 1e+07 cells/kg Intravenous
Subject TCR-like CAR-T Cell therapy 2e+07 cells/kg Intravenous

Indications

No indication recorded.